CytoSolve

From Wikipedia, the free encyclopedia
Jump to: navigation, search

CytoSolve, Inc. is a US-based corporation, which has created a technology platform for in silico drug discovery and development through quantitative modeling of complex molecular pathways - potentially supplanting the need for animal testing and reducing the time it takes for drugs or nutraceuticals to be brought to market.[1][2] CytoSolve specializes in the use of its technology platform for discovery of multi-combination compounds for both the prevention and cure of major diseases such as cancer, obesity, inflammation and others.[3]

The company was incorporated as a Delaware Corporation on 7 March 2011.[4]

History[edit]

CytoSolve was founded in 2011 by Dr. VA Shiva Ayyadurai, an inventor, systems scientist and MIT-trained systems biologist, following his doctoral research in molecular systems biology at the Massachusetts Institute of Technology (M.I.T.), department of Biological Engineering, and his field work in eastern and traditional systems of medicine such as Siddha, Ayurveda and Traditional Chinese Medicine.[5][6][7] The company was incorporated as a Delaware corporation, with its place of business in Cambridge, Massachusetts.[8]

In 2011, Dr. VA Shiva Ayyadurai provided the initial seed capital for the company. In 2012, the company received its first round of funding from early-stage private investors. Dr. Deepak Chopra, a medical doctor and pioneer in integrative medicine, and founder of the Chopra Center for Well Being, as well as Thomas Zawacki, an Internet pioneer and creator of Lemonade.Com, joined the Board of Directors of CytoSolve in 2013.[9]

Scientific Relevance[edit]

CytoSolve’s core technology platform, provides a method for drug development as well as for developing combinatorial drug therapies, has been the basis of scientific study and interest in a number of university research projects.[10][11][12]

In 2006, the National Science Foundation issued a grand challenge to create a computational or mathematical model of the whole human cell.[13] In 2007, Dr. VA Shiva Ayaydurai developed a software platform called CytoSolve that provided a computational architecture for whole cell modeling, by providing a mechanism to integrate large-scale molecular pathway models.[14] In 2010, a peer-reviewed journal article entitled "A Scalable Computational Method for Dynamic Integration of Multiple Molecular Pathway Models" was published.[15] In 2011, another paper which described the architecture of the CytoSolve approach for whole cell modeling was published.[16]

In order to model the whole cell, multi-scale modeling is of importance, a critical feature that CytoSolve provides.[17] A scientific paper titled "Combinatorial drug therapy for cancer in the post-genomic era" published in Nature America's July 2012 issue states that "Computational protocols, such as CytoSolve, allow the combination of alternative models and generation of consensus hypotheses."[18] A scientific paper titled “Setting a Research Agenda for Progressive MS: The International Collaborative on Progressive MS” cited CytoSolve as "… techniques hold promise to provide the tools for interpreting genetic data across different knowledge domains."[19]

References[edit]

  1. ^ "About CytoSolve Platform". www.cytosolve.com. CytoSolve, Inc. Retrieved 9 April 2013. 
  2. ^ Mertz, L (4 April 2013). "Creating Accurate Models of Life: Merging Biology and Computer Science", published in March 2013". Pulse, IEEE 4 (2): 16–25. doi:10.1109/MPUL.2013.2244961. ISSN 2154-2287. Retrieved 10 April 2013. 
  3. ^ Al-Lazikani B; Banerji U; Workman P (10 July 2012). "Combinatorial drug therapy for cancer in the post-genomic era". Nat Biotechnol 30 (7): 679–692. doi:10.1038/nbt.2284. PMID 22781697. Retrieved 9 April 2013. 
  4. ^ "CytoSolve, Inc. Corporate Information". massachusettscompanies.org. Massachusetts Business Directory of Business Contacts and Company Information. Retrieved 9 April 2013. 
  5. ^ "About Us page". www.cytosolve.com. CytoSolve, Inc. Retrieved 9 April 2013. 
  6. ^ Mertz, L (4 April 2013). "Creating Accurate Models of Life: Merging Biology and Computer Science", published in March 2013". Pulse, IEEE 4 (2): 16–25. doi:10.1109/MPUL.2013.2244961. ISSN 2154-2287. Retrieved 10 April 2013. 
  7. ^ Trafton, Anne (September 17, 2007). "East meets West Armed with 4 MIT degrees, Shiva Ayyadurai embarks on new adventure". MIT news. Retrieved 16 April 2013. 
  8. ^ "Contact Us page". CytoSolve Corporate Website. CytoSolve, Inc. Retrieved 16 April 2013. 
  9. ^ "What we do page: News". cytosolve.com. CytoSolve, Inc. Retrieved 9 April 2013. 
  10. ^ Ayyadurai, Shiva. "Integrating an Ensemble of Distributed Biochemical Network Models". 15th International Conference, Vienna, Austria, 21–25 July 2007. Intelligent Systems for Molecular Biology (ISMB). Retrieved 9 April 2013. 
  11. ^ Ayyadurai, Shiva. "A Distributed Computational Architecture for Integrating Multiple Biomolecular Pathways". Dspace@MIT. Massachusetts Institute of Technology. Retrieved 9 April 2013. 
  12. ^ Ayyadurai, Shiva. "OREMPdb: a semantic dictionary of computational pathway models". Dspace@MIT. Massachusetts Institute of Technology. Retrieved 9 April 2013. 
  13. ^ Omenn, Gilbert S. (15 December 2006). "Grand Challenges and Great Opportunities in Science, Technology, and Public Policy". Science 314 (5806): 1696–1704. doi:10.1126/science.1135003. Retrieved 16 April 2013. 
  14. ^ Ayyadurai, Shiva. "A Distributed Computational Architecture for Integrating Multiple Biomolecular Pathways". Dspace@MIT. Massachusetts Institute of Technology. Retrieved 9 April 2013. 
  15. ^ Ayyadurai, VA Shiva; Dewey, C. Forbes (March 2011). "CytoSolve: A Scalable Computational Method for Dynamic Integration of Multiple Molecular Pathway Models". Cell Mol Bioeng. (Springer) 4 (1): 28–45. doi:10.1007/s12195-010-0143-x. PMC 3032229. PMID 21423324. Retrieved 22 March 2013. 
  16. ^ Ayyadurai, VA Shiva (2011). "Services-Based Systems Architecture for Modeling the Whole Cell: A Distributed Collaborative Engineering Systems Approach". Future Visions on Biomedicine and Bioinformatics 1 1: 115–168. doi:10.1007/8754_2010_1. Retrieved 16 April 2013. 
  17. ^ Nordsletten, DA; et al. (December 2011). "Multiscale mathematical modeling to support drug development". IEEE Trans Biomed Eng 58 (12): 3508–12. doi:10.1109/TBME.2011.2173245. PMID 22042123. Retrieved 16 April 2013. 
  18. ^ Al-Lazikani B; Banerji U; Workman P (10 July 2012). "Combinatorial drug therapy for cancer in the post-genomic era". Nat Biotechnol 30 (7): 679–692. doi:10.1038/nbt.2284. PMID 22781697. Retrieved 9 April 2013. 
  19. ^ Fox RJ,; et al. (23 August 2012). "Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS". Mult Scler 18 (11): 1534–40. doi:10.1177/1352458512458169. PMID 22917690. Retrieved 9 April 2013.